The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Open accessAbstract
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The possible contribution of the adaptive immune system in AD patients to reducing cancer incidence has not been studied (4,5).”
From Alzheimer's Disease–Associated Amyloid-β Precursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Typically, PD‐L1 or PD‐L2 are expressed on the surface of cancer cells or antigen‐presenting cells and transduce a signal for cooperation with PD‐1 expression on the cell surface of T lymphocytes to stimulate restraint signaling [272, 273].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cited by
Sorted by citations
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordão, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,718
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Gerstberger, S. C., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 1,010
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 986
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 818
The cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 740
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
CD8+ T Cell Exhaustion in Cancer
Dolina, J. S., Budimir, N., Thomas, G. D., & Salek‐Ardakani, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715234 · Cited by 504
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
Islami, F., Ward, E., Sung, H., Cronin, K. A., Tangka, F. K. L., Sherman, R., Zhao, J., Anderson, R. N., Henley, S. J., Yabroff, K. R., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab131 · Cited by 490
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 478
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 502
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2021) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 451
A pan-cancer single-cell panorama of human natural killer cells
Tang, F., Li, J., Qi, L., Liu, D., Bo, Y., Qin, S., Miao, Y., Yu, K., Hou, W., Li, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.034 · Cited by 450
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A., Zurke, Y.-X., & Monaco, C. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 455
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Patil, N. S., Nabet, B. Y., Müller, S., Koeppen, H., Zou, W., Giltnane, J. M., Au‐Yeung, A., Srivats, S., Cheng, J. H., Takahashi, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.002 · Cited by 423
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras‐Murillo, I., Adán‐Barrientos, I., Galán, M. Á., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 418
Sleeboom, J. J. F., van Tienderen, G. S., Schenke‐Layland, K., van der Laan, L. J. W., Khalil, A., & Verstegen, M. M. A. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3840 · Cited by 401
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 399
Modes of Regulated Cell Death in Cancer
Koren, E., & Fuchs, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0789 · Cited by 388
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 368
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Tumor-associated macrophages: an effective player of the tumor microenvironment
Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., & Sa, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295257 · Cited by 356
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A.-T. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 352
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 339
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Kruse, B., Buzzai, A. C., Shridhar, N., Braun, A. D., Gellert, S., Knauth, K., Poźniak, J., Peters, J., Dittmann, P., Mengoni, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06199-x · Cited by 353
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 341
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 318
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
The chemistry and applications of hafnium and cerium( iv ) metal–organic frameworks
Hu, Z., Wang, Y., & Zhao, D. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00920b · Cited by 303
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 311
Friedrich, M., Neri, P., Kehl, N., Michel, J., Steiger, S., Kilian, M., Leblay, N., Maity, R., Sankowski, R., Lee, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.008 · Cited by 289
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Li, T., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 297
Li, J., Liu, J., Zhou, Z., Wu, R., Chen, X., Yu, C., Stockwell, B. R., Kroemer, G., Kang, R., & Tang, D. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3049 · Cited by 305
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. Q. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 297
COVID-19 and Cancer: Current Challenges and Perspectives
Bakouny, Z., Hawley, J. E., Choueiri, T. K., Peters, S., Rini, B. I., Warner, J. L., & Painter, C. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.018 · Cited by 276
MYB orchestrates T cell exhaustion and response to checkpoint inhibition
Tsui, C., Kretschmer, L., Rapelius, S., Gabriel, S. S., Chisanga, D., Knöpper, K., Utzschneider, D. T., Nüssing, S., Liao, Y., Mason, T., et al. (2022) · Nature · doi:10.1038/s41586-022-05105-1 · Cited by 264
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 296
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J. J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 273
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Intratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 269
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 300
Cancer evolution: Darwin and beyond
Vendramin, R., Litchfield, K., & Swanton, C. (2021) · The EMBO Journal · doi:10.15252/embj.2021108389 · Cited by 269
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
Hypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Pérez-Ruiz, E., Sarmento‐Ribeiro, A. B., Saponara, S., Rivas, J. D. L., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 264
To NMD or Not To NMD: Nonsense-Mediated mRNA Decay in Cancer and Other Genetic Diseases
Supek, F., Lehner, B., & Lindeboom, R. G. H. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.11.002 · Cited by 243
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 245
Thermal immuno-nanomedicine in cancer
Yang, Z., Gao, D., Zhao, J., Yang, G., Guo, M., Wang, Y., Ren, X., Kim, J. S., Jin, L., Tian, Z., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00717-y · Cited by 255
Mechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 252
Wang, C., Yu, Q., Song, T., Wang, Z., Song, L., Yang, Y., Shao, J., Li, J., Ni, Y., Chao, N., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01130-8 · Cited by 255
Chronic inflammation, cancer development and immunotherapy
Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., & Tang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040163 · Cited by 247
Jiang, Z., Wang, W., Xu, C., Xie, Y., Wang, X., Zhang, Y., Huang, J., Huang, M., Xie, C., Liu, P., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.019 · Cited by 234
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Chiang, E. Y., & Mellman, I. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004711 · Cited by 235
Patient-derived micro-organospheres enable clinical precision oncology
Ding, S., Hsu, C., Wang, Z., Natesh, N. R., Millen, R., Negrete, M., Giroux, N., Rivera, G. O., Dohlman, A., Bose, S., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.04.006 · Cited by 228
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 243
Targeting innate immune pathways for cancer immunotherapy
Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 234
Cancers make their own luck: theories of cancer origins
Jassim, A., Rahrmann, E. P., Simons, B. D., & Gilbertson, R. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00602-5 · Cited by 236
Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
Igarashi, Y., & Sasada, T. (2020) · Journal of Immunology Research · doi:10.1155/2020/5825401 · Cited by 226
Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy
Nenkov, M., Ma, Y., Gaßler, N., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126262 · Cited by 226
Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment
Baharom, F., Ramirez-Valdez, R. A., Khalilnezhad, A., Khalilnezhad, S., Dillon, M., Hermans, D., Fussell, S. C., Tobin, K. K. S., Dutertre, C., Lynn, G. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.10.006 · Cited by 220
MIF-Dependent Control of Tumor Immunity
Noe, J. T., & Mitchell, R. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609948 · Cited by 198
Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalçın, Ş. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 220
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
Zeng, Y., & Jin, R. U. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.004 · Cited by 221
T follicular helper cells in cancer
Gutiérrez-Melo, N., & Baumjohann, D. (2023) · Trends in cancer · doi:10.1016/j.trecan.2022.12.007 · Cited by 219
NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates
Yang, D., Sun, B., Li, S., Wei, W., Liu, X., Cui, X., Zhang, X., Liu, N., Yan, L., Deng, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1951 · Cited by 217
Si, J., Shi, X., Sun, S., Zou, B., Li, Y., An, D., Lin, X., Gao, Y., Long, F., Pang, B., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.001 · Cited by 209
Immune cell - produced ROS and their impact on tumor growth and metastasis
Kennel, K. B., & Greten, F. R. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101891 · Cited by 213
Spatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 227
Can we predict T cell specificity with digital biology and machine learning?
Hudson, D., Fernandes, R. A., Basham, M., Ogg, G. S., & Koohy, H. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00835-3 · Cited by 209
Meiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S. B., Pedde, A., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 208
Nersesian, S., Schwartz, S. L., Grantham, S. R., MacLean, L. K., Lee, S. N., Pugh-Toole, M., & Boudreau, J. E. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100930 · Cited by 197
Role of serotonin receptor signaling in cancer cells and anti-tumor immunity
Karmakar, S., & Lal, G. (2021) · Theranostics · doi:10.7150/thno.55986 · Cited by 203
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
Pan, R. A., Ryan, J. A., Pan, D., Wucherpfennig, K. W., & Letai, A. G. (2022) · Cell · doi:10.1016/j.cell.2022.03.030 · Cited by 204
Chromatin accessibility profiling methods
Minnoye, L., Marinov, G. K., Krausgruber, T., Pan, L., Marand, A. P., Secchia, S., Greenleaf, W. J., Furlong, E. E. M., Zhao, K., Schmitz, R. J., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-020-00008-9 · Cited by 206
Age-associated remodeling of T cell immunity and metabolism
Han, S., Georgiev, P., Ringel, A. E., Sharpe, A. H., & Haigis, M. C. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.005 · Cited by 200
Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0384 · Cited by 191
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Dejenie, T. A., Medhin, M. T. G., Terefe, G. D., Admasu, F. T., Tesega, W. W., & Abebe, E. C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 210
Regulation of Treg cells by cytokine signaling and co-stimulatory molecules
Zong, Y., Deng, K., & Chong, W. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1387975 · Cited by 202
Bonney, G. K., Chew, C. A. Z., Lodge, P. A., Hubbard, J. M., Halazun, K. J., Trunečka, P., Muiesan, P., Mirza, D. F., Isaac, J., Laing, R. W., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00219-3 · Cited by 191
Magré, L., Verstegen, M. M. A., Buschow, S. I., van der Laan, L. J. W., Peppelenbosch, M. P., & Desai, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006290 · Cited by 201
The Role of Viral Infections in the Onset of Autoimmune Diseases
Sundaresan, B., Shirafkan, F., Ripperger, K., & Rattay, K. (2023) · Viruses · doi:10.3390/v15030782 · Cited by 204
Advances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 187
MacNabb, B. W., Chen, X., Tumuluru, S., Godfrey, J. K., Kasal, D. N., Yu, J., Jongsma, M. L. M., Spaapen, R. M., Kline, D. E., & Kline, J. P. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.016 · Cited by 189
Zhu, Y., Zhou, Z., Du, X., Lin, X., Liang, Z.-M., Chen, S., Sun, Y., Wang, Y., Na, Z., Wu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.015 · Cited by 200
Li, J. J. X., Tsang, J. Y., & Tse, G. M.-K. (2021) · Cancers · doi:10.3390/cancers13164233 · Cited by 190
Sas, Z., Cendrowicz, E., Weinhäuser, I., & Rygiel, T. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073778 · Cited by 184
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer
Zhou, P., Shi, H., Huang, H., Sun, X., Yuan, S., Chapman, N. M., Connelly, J. P., Lim, S. A., Saravia, J., Anil, K. C., et al. (2023) · Nature · doi:10.1038/s41586-023-06733-x · Cited by 190
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Gallego‐Ortega, D., & Deng, W. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 190
Nachef, M., Ali, A. K., Almutairi, S. M., & Lee, S.-H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624324 · Cited by 182
Cao, L., Tian, H., Fang, M., Xu, Z., Tang, D., Chen, J., Yin, J., Xiao, H., Shang, K., Han, H., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121856 · Cited by 179
Taifour, T., Attalla, S. S., Zuo, D., Gu, Y., Sanguin‐Gendreau, V., Proud, H., Solymoss, E., Bui, T., Kuasne, H., Papavasiliou, V., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.002 · Cited by 178
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda, R., Dimou, P., D’Souza, R. R., & Klampatsa, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s291767 · Cited by 184
Tumor inflammation-associated neurotoxicity
Mahdi, J., Dietrich, J., Straathof, K. C. M., Roddie, C., Scott, B. J., Davidson, T. B., Prolo, L. M., Batchelor, T. T., Campen, C. J., Davis, K. L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02276-w · Cited by 176
Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy
Xia, W., Tao, Z., Zhu, B., Zhang, W., Liu, C., Chen, S., & Song, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179118 · Cited by 177
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
Liu, S., Wang, W., Hu, S., Jia, B., Tuo, B., Sun, H., Wang, Q., Liu, Y., & Sun, Z. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06211-2 · Cited by 194
Metadata
- Authors
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lenardo, Michael J.
- Venue
- Nature Reviews Immunology
- Published
- 2020-05-20
- Volume
- 20
- Issue
- 11
- Pages
- 651-668
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7238960
- OpenAlex
- W3028523516
- Cited by
- 4,154
- References
- 302
- Citations by year
- 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
- FWCI
- 58.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Emory University
- National Institutes of Health
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
